UY37534A - Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda - Google Patents
Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambdaInfo
- Publication number
- UY37534A UY37534A UY0001037534A UY37534A UY37534A UY 37534 A UY37534 A UY 37534A UY 0001037534 A UY0001037534 A UY 0001037534A UY 37534 A UY37534 A UY 37534A UY 37534 A UY37534 A UY 37534A
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- interferon
- lambda
- fibrotic diseases
- fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de la fibrosis. La invención describe una nueva investigación que demuestra que el interferón lambda tiene efectos antifibróticos que actúan directamente tanto in vitro como in vivo y puede usarse para proporcionar nuevas terapias eficaces para el tratamiento de múltiples tipos de la fibrosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1621728.3A GB201621728D0 (en) | 2016-12-20 | 2016-12-20 | Methods |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37534A true UY37534A (es) | 2018-09-28 |
Family
ID=58284677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037534A UY37534A (es) | 2016-12-20 | 2017-12-20 | Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190374610A1 (es) |
EP (1) | EP3558342A1 (es) |
JP (2) | JP2020511415A (es) |
CN (1) | CN110381985A (es) |
AR (1) | AR110404A1 (es) |
BR (1) | BR112019012084A2 (es) |
CA (1) | CA3044949A1 (es) |
EA (1) | EA201991175A1 (es) |
GB (1) | GB201621728D0 (es) |
TW (1) | TW201828973A (es) |
UY (1) | UY37534A (es) |
WO (1) | WO2018115199A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020041636A1 (en) * | 2018-08-23 | 2020-02-27 | Exalt Therapeutics, Llc | Modified ifnl3 polypeptides comprising a pharmacokinetic enhancing moiety and their uses |
JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
CN110882381B (zh) * | 2019-12-18 | 2020-11-17 | 中国人民解放军陆军军医大学第一附属医院 | 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用 |
WO2021119749A1 (en) * | 2019-12-20 | 2021-06-24 | The Council Of The Queensland Institute Of Medical Research | Treatment of gastrointestinal disease |
CN114736878B (zh) * | 2021-01-07 | 2024-04-19 | 秦皇岛摩登狗生物科技有限公司 | 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
HUP0303645A3 (en) | 2001-04-06 | 2005-12-28 | Maxygen Holdings Ltd Georgetow | Interferon gamma polypeptide variants |
EP1551369A4 (en) | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
WO2004078207A1 (en) | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
WO2004078194A1 (en) | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
WO2004105684A2 (en) | 2003-05-16 | 2004-12-09 | Intermune, Inc. | Combination therapy for proliferative disorders |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005067454A2 (en) * | 2003-12-23 | 2005-07-28 | Valeant Pharmaceuticals North America | Combination therapy for treating hepatitis c virus infection |
WO2005110478A2 (en) | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2009529027A (ja) | 2006-03-08 | 2009-08-13 | ビオメトード | ヒトインターフェロンガンマ(IFNγ)変異体 |
ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
CA2727026A1 (en) * | 2008-06-05 | 2009-12-10 | Zymogenetics, Llc | Use of pegylated type iii interferons for the treatment of hepatitis c |
EP2344546A1 (en) | 2008-10-13 | 2011-07-20 | Zymogenetics, Inc. | Single chain fc type iii interferons and methods of using same |
WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
EP2350124A1 (en) * | 2008-11-20 | 2011-08-03 | Zymogenetics, Inc. | Il-29 mutants and uses thereof |
WO2011075605A2 (en) * | 2009-12-18 | 2011-06-23 | Alios Biopharma, Inc. | Hyperglycosylated interferon variants and methods of use |
IT1400236B1 (it) | 2010-05-10 | 2013-05-24 | Univ Bari | Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc) |
CN102584979B (zh) * | 2011-01-18 | 2015-10-14 | 北京凯因科技股份有限公司 | PEG化干扰素λ |
CA2869899C (en) | 2012-03-28 | 2021-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A novel interferon-.lambda.4 (ifnl4) protein, related nucleic acid molecules, and uses thereof |
JP2019505553A (ja) * | 2016-02-19 | 2019-02-28 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
-
2016
- 2016-12-20 GB GBGB1621728.3A patent/GB201621728D0/en not_active Ceased
-
2017
- 2017-12-20 BR BR112019012084-0A patent/BR112019012084A2/pt not_active IP Right Cessation
- 2017-12-20 CN CN201780077416.5A patent/CN110381985A/zh active Pending
- 2017-12-20 TW TW106144926A patent/TW201828973A/zh unknown
- 2017-12-20 EA EA201991175A patent/EA201991175A1/ru unknown
- 2017-12-20 JP JP2019532000A patent/JP2020511415A/ja active Pending
- 2017-12-20 UY UY0001037534A patent/UY37534A/es not_active Application Discontinuation
- 2017-12-20 AR ARP170103597A patent/AR110404A1/es unknown
- 2017-12-20 US US16/469,236 patent/US20190374610A1/en not_active Abandoned
- 2017-12-20 CA CA3044949A patent/CA3044949A1/en not_active Abandoned
- 2017-12-20 WO PCT/EP2017/083949 patent/WO2018115199A1/en unknown
- 2017-12-20 EP EP17829194.4A patent/EP3558342A1/en active Pending
-
2022
- 2022-03-23 JP JP2022046767A patent/JP2022081677A/ja active Pending
-
2023
- 2023-06-29 US US18/343,944 patent/US11975046B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112019012084A2 (pt) | 2019-11-12 |
EP3558342A1 (en) | 2019-10-30 |
TW201828973A (zh) | 2018-08-16 |
WO2018115199A1 (en) | 2018-06-28 |
JP2022081677A (ja) | 2022-05-31 |
EA201991175A1 (ru) | 2019-11-29 |
CN110381985A (zh) | 2019-10-25 |
US20190374610A1 (en) | 2019-12-12 |
US20240000893A1 (en) | 2024-01-04 |
GB201621728D0 (en) | 2017-02-01 |
US11975046B2 (en) | 2024-05-07 |
CA3044949A1 (en) | 2018-06-28 |
JP2020511415A (ja) | 2020-04-16 |
AR110404A1 (es) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37534A (es) | Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda | |
IL290809B1 (en) | Tau-protein targeted protacs and related methods of use | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
GT201700081A (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
GT201600185A (es) | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
CL2015002807A1 (es) | Terapia de combinación | |
UY34675A (es) | ?proceso y aparato para tratar superficies de metal?. | |
MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
MX2019005779A (es) | Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. | |
CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
SG10201405683YA (en) | Emission Source And Method Of Forming The Same | |
CL2015002181A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. | |
IL248080A0 (en) | System and method for identifying sources associated with biological arrhythmias | |
CL2016001098A1 (es) | Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales | |
EP3423881A4 (en) | SYSTEM AND METHOD FOR IMAGING WITH DIFFUSION TO REDUCE SOURCE SELF-FLUORESCENCE AND IMPROVE UNIFORMITY | |
EP3325095A4 (en) | SYSTEM AND METHOD FOR THE APPLICATION OF LIGHT THERAPY TO CURVED AND LARGE SURFACES | |
PH12016502284A1 (en) | Cough medicine containing ambroxol hydrochloride | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
BR112015019792A2 (pt) | composição para tratamento de hemorróidas e método de preparação | |
UA115417U (xx) | Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230705 |